Carolinas HealthCare System

Saad Z. Usmani, MD

Hematology - Medical Oncology
  • Clinical Interests
  • Biography
Levine Cancer Institute
1021 Morehead Medical Drive
Charlotte, NC 28204
Phone: 980-442-2000
Get Directions | View Map

Practice Website
Hematology - Medical Oncology
Medical Oncology - Cancer
Sinai-Grace Hospital, Michigan
Specialty: Internal Medicine
University of Connecticut Health Center, Connecticut
Specialty: Hematology and Medical Oncology

Allama Iqbal Medical College, Pakistan
There was an issue with the publications feed.
Publications There was an issue with the publications feed. Clinical Interest
  • Bone Marrow Transplant
  • Hematology
  • Oncology
  • Medical Oncology
  • Lymphoma
  • Myeloma
  • Plasma Cell Disorders
Biography Saad Zafar Usmani, M.D., FACP joined Levine Cancer Institute as the Director of Plasma Cell Disorder program and the Director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute/Carolinas Healthcare System. He is a specialist in Hematology, Medical Oncology and Bone Marrow Transplantation. He also holds an academic appointment as Clinical Associate Professor of Medicine at the UNC-Chapel Hill School of Medicine. Dr. Usmani received his medical education at Allama Iqbal Medical College Lahore, Pakistan. He completed a residency in Internal Medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan, and a fellowship in Hematology & Oncology at the University of Connecticut Health Center in Farmington, Connecticut. Prior to joining LCI, Dr. Usmani was an Assistant Professor of Medicine at the University of Arkansas for Medical Sciences in Little Rock, AR where he served as the Director of Developmental Therapeutics at the Myeloma Institute for Research & Therapy. His clinical and translational research has been focused on plasma cell disorders in general, and high-risk multiple myeloma in specific.

He is a member of the International Myeloma Working Group, the SWOG Myeloma Committee, the Bone Marrow Transplant- Clinical Trials Network Myeloma Committee, the American Society of Hematology, the American Society of Clinical Oncology and the American Society of Bone Marrow Transplantation. He is also serving on the ASCO Scientific Committee on Lymphoma and Plasma Cell Disorders, and the ASH Committee on Plasma Cell Neoplasia. He is on the editorial review board of numerous medical journals, and has presented extensively at national and international meetings.